Goji berries vs. fiber for age-related macular degeneration
Part of Eyes & vision clinical trials.
This study compares the effects of eating goji berries versus taking fiber wafers on age-related macular degeneration (AMD). It looks at whether goji berries or fiber can help slow down the eye condition, especially for people with a family history of AMD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 65 and 95 years old.
- You must have a family history of age-related macular degeneration (AMD) in a parent, sibling, or child.
- You must have high cholesterol or diabetes that is well-managed.
- You cannot be allergic to goji berries or ingredients in the fiber wafers (wheat, corn, oats, soy, orange flavor, xylitol, annatto, pectin).
- You cannot be taking blood thinners (like warfarin) or have plans to take them during the study.
- You cannot take multivitamins or supplements that contain lutein or zeaxanthin unless you stop them for at least 6 months before enrolling.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking omega-3 fatty acids can slow the worsening of dry age-related macular degeneration (AMD) in people with early or intermediate disease. It may help by testing if omega-3 changes how the retina changes over time.
This study tests whether taking daily supplements of lutein, zeaxanthin, and fish oil can improve the protective pigment in your eyes. It may help people with low macular pigment and good vision who are not already taking high doses of these nutrients.
This study tests whether improving your diet through online meetings can help slow early age-related macular degeneration (AMD), a condition affecting vision. You'll meet with a counselor remotely to make healthier food choices.
This study uses a special camera to take pictures of the back of your eye (retina) to see how age-related macular degeneration (AMD) affects everyday activities like reading and recognizing faces. It also compares people with AMD to healthy volunteers to understand the differences.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.